- Project Summary
- Study Duration
- Objectives
- Outcomes
- Team Members
- Publications
Project Summary
The Surveillance of Enteric Fever in Asia Project (SEAP) project has been operating in Nepal for 5 years with approval from NHRC granted in September 2016. SEAP is a multi-site prospective cohort study that has been generating data to inform policy recommendations on enteric fever prevention and control, as well as facilitate typhoid vaccine implementation. Here we propose to extend the SEAP Phase II study for two (2022-2024) more years and add an additional, complementary component: Case control study to study effectiveness of recently introduced typhoid This study will address some shortcomings of previous studies and fill knowledge gaps regarding enteric fever in Asia through collection and synthesis of existing and prospective information especially measure the impact of the recently introduced typhoid vaccine in routine immunization on antimicrobial resistance, effectiveness and measure potential serotype replacement by Salmonella Paratyphi A. Previous studies have identified high burden of Salmonella in Kathmandu and Kavre and vicinity as well as resistance pattern of Salmonella. SEAP project overall objectives are to characterize the burden of enteric fever in Nepal, including clinical manifestations, severity of illness, long-term sequelae of illness, antimicrobial resistance patterns of enteric fever isolates, evaluate new diagnostics and measure the vaccine impact.
This study will generate data to facilitate the assessment of the impact of typhoid vaccine while also characterizing risk factors for development of severe illness among enteric fever cases. This study currently collects data by combining hospital-based inpatient and outpatient surveillance and laboratory surveillance to estimate disease burden for enteric fever. SEAP study include two prospective sites i.e. Dhulikhel Hospital and Kathmandu Model hospital. There are seven retrospective sites.
These facilities include Bir Hospital, Nepal Medical College, Helping Hands Community Hospital, Kanti Children’s Hospital, Ishan women and Children’s Hospital, Civil Service Hospital, Siddhi Memorial women and Children Hospital. Study requires 7668 enteric fever or suspected patient for the study. SEAP project also include long-term six-follow-up of all blood culture confirmed cases to assess rates of relapse, mortality, and morbidity to characterize the economic burden of enteric fever in Nepal. SEAP study will help in estimate incidence of enteric fever in Nepal, Hospital based incidence of enteric fever complications, duration of hospitalization and case fatality rate, frequency of antimicrobial resistance for S. Typhi and Paratyphi isolated from enteric fever cases through genotypic and phenotypic analysis. SEAP also help in determining effectiveness of BioE TCV introduced by Nepal government in prevention of symptomatic, culture-confirmed enteric fever.
Study Duration
From 10/01/2022 – 12/31/2024
Objectives
The general objective of SEAP project is to characterize the burden of enteric fever in Nepal before and after the introduction of typhoid vaccine, including clinical manifestations, severity of illness, long-term sequelae of illness, antimicrobial resistance patterns of enteric fever isolates.  The study also aims to evaluate the direct effectiveness of the typhoid conjugate vaccine TCV using a test-negative case control design, comparing culture-confirmed typhoid cases with culture-negative controls
Outcomes
This study helps in calculating incidence estimates for enteric fever infections, with age and spatial trends, Hospital-based incidence of enteric fever complications, duration of hospitalization and case fatality rate. This study also evaluates the frequency of antimicrobial resistance for S. Typhi and Paratyphi isolated from enteric fever cases through genotypic and phenotypic analysis and clinical features and distribution of typhoid and other undifferentiated acute febrile illnesses. The study also evaluates the effectiveness of BioE TCV in prevention of symptomatic, culture-confirmed enteric fever.
Team Members
Principal Investigator(s): Dr. Dipesh Tamrakar, Prof. Dr. Jason Andrews
Co-Investigator(s): Prof. Dr. Rajeev Shrestha, Dr. Basudha Shrestha
Project Coordinator(s): Mr. Shiva Ram Naga, Mr. Sabin Bikram Shahi
Research Assistants: Ms. Aarjya Tara Bajracharya, Ms. Natasha Shrestha, Ms. Nisha Shrestha, Mr. Suraj Jakibanjar, Ms. Mamata Maharjan, Mr. Suvash Tamang, Ms. Nisha Ale
Supported by: Sabin Vaccine Institute, USA
Collaborating Partner: Stanford University, San Francisco, USA
Publications
- Tamrakar D, Naga SR, Jung E, Shrestha B, Bista Roka P, Pokharel R, et al. Impact of the COVID-19 pandemic and typhoid conjugate vaccine introduction on typhoid fever in Nepal. PLoS Negl Trop Dis. 2026 Jan;20(1):e0013242. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12851488/
- Tamrakar D, Shah SB, Jung E, Naga S, Shrestha B, Roka PB, et al. Effectiveness of the TYPHIBEV® (Vi-CRM197 conjugate) vaccine introduction in Nepal: a test-negative, case-control study [Internet]. medRxiv. November 2025. Available from: http://medrxiv.org/lookup/doi/10.1101/2025.11.20.25340644








